BR9608449A - Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. - Google Patents

Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.

Info

Publication number
BR9608449A
BR9608449A BR9608449-9A BR9608449A BR9608449A BR 9608449 A BR9608449 A BR 9608449A BR 9608449 A BR9608449 A BR 9608449A BR 9608449 A BR9608449 A BR 9608449A
Authority
BR
Brazil
Prior art keywords
virus
defective recombinant
pharmaceutical composition
adenoviruses
recombinant virus
Prior art date
Application number
BR9608449-9A
Other languages
English (en)
Inventor
Didier Branellec
Kenneth Walsh
Jeffrey M Isner
Patrice Denefle
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of BR9608449A publication Critical patent/BR9608449A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"VìRUS RECOMBINANTE DEFEITUOSO, ADENOVìRUS, USO DE UM VìRUS, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a vírus recombinantes defeituosos, que contêm pelo menos um gene inserido codificando toda ou parte da proteína GAX ou de uma variante desta proteína, e a seu uso terapêutico, em particular para tratar restenose pós-angioplástica.
BR9608449-9A 1995-03-31 1996-03-28 Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. BR9608449A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504234A FR2732357B1 (fr) 1995-03-31 1995-03-31 Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
PCT/US1996/004493 WO1996030385A1 (en) 1995-03-31 1996-03-28 Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis

Publications (1)

Publication Number Publication Date
BR9608449A true BR9608449A (pt) 1999-11-30

Family

ID=9477928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608449-9A BR9608449A (pt) 1995-03-31 1996-03-28 Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.

Country Status (16)

Country Link
US (2) US5851521A (pt)
EP (1) EP0817791A4 (pt)
JP (1) JPH11503314A (pt)
KR (1) KR19980703454A (pt)
CN (1) CN1190402A (pt)
AP (1) AP1011A (pt)
AU (1) AU701345B2 (pt)
BR (1) BR9608449A (pt)
CA (1) CA2216878A1 (pt)
CZ (1) CZ308897A3 (pt)
FR (1) FR2732357B1 (pt)
HU (1) HUP9801767A3 (pt)
OA (1) OA10516A (pt)
SI (1) SI9620059A (pt)
SK (1) SK132797A3 (pt)
WO (1) WO1996030385A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
FR2740344B1 (fr) * 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers
FR2754822B1 (fr) * 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
WO2000041732A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
CA2396628A1 (en) 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
AU3988401A (en) * 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US20030100889A1 (en) * 2001-07-05 2003-05-29 Nicolas Duverger Method of administration of a gene of interest to a vascular tissue
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
US20040220656A1 (en) * 2003-04-30 2004-11-04 Epstein Samuel J. Coated medical devices and methods of making the same
US20080215137A1 (en) * 2003-04-30 2008-09-04 Boston Scientific Scimed, Inc. Therapeutic driving layer for a medical device
US20050120398A1 (en) * 2003-09-12 2005-06-02 Vertex Pharmaceuticals Incorporated Animal model for HCV infection
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7582442B2 (en) * 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
WO2006014798A2 (en) * 2004-07-27 2006-02-09 Mount Sinai School Of Medicine Methods and compositions for using sax2
FI20050753A (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
WO2006101629A2 (en) 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
AU2007254243B2 (en) 2006-05-17 2013-06-13 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
WO2009088256A2 (ko) 2008-01-09 2009-07-16 Konkuk University Industrial Cooperation Corp 배큘로바이러스-기반 백신
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EP2318036B1 (en) 2008-06-30 2015-06-03 The Regents of the University of Michigan Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
KR101230913B1 (ko) 2009-11-06 2013-02-07 중앙대학교 산학협력단 나노입자-기반된 유전자 운반체
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
CA2840175C (en) 2011-05-19 2021-11-16 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
US9404090B2 (en) 2011-11-24 2016-08-02 Viromed Co., Ltd. Adenovirus producing novel cell line and the use thereof
DK2785683T3 (da) 2011-11-30 2020-04-14 Ludwig Inst For Cancer Res Ltd Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
PL3421602T3 (pl) 2012-09-06 2021-10-25 The University Of Chicago Polinukleotydy antysensowne wywołujące pominięcie egzonu i sposoby leczenia dystrofii
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
DK3283500T3 (en) 2015-04-08 2020-11-16 Univ Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
CN108289920A (zh) 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
JP6913747B2 (ja) 2016-09-20 2021-08-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ イヌアデノウイルスベクター
AU2017329672B2 (en) 2016-09-20 2023-07-27 Boehringer Ingelheim Vetmedica Gmbh New promoters
US10619169B2 (en) 2016-09-20 2020-04-14 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site ORF70
KR102566066B1 (ko) 2016-09-20 2023-08-16 베링거잉겔하임베트메디카게엠베하 신규한 돼지 인플루엔자 백신
CN111630159A (zh) 2017-12-13 2020-09-04 基因药物株式会社 重组腺病毒及包含此病毒的干细胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
CA1339354C (en) * 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69333886T2 (de) * 1992-11-18 2006-07-27 Arch Development Corp., Chicago Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
EP0911413A3 (en) * 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene

Also Published As

Publication number Publication date
CZ308897A3 (cs) 1998-03-18
USRE37933E1 (en) 2002-12-10
FR2732357A1 (fr) 1996-10-04
HUP9801767A2 (hu) 1998-10-28
AP1011A (en) 2001-09-22
AP9701117A0 (en) 1996-03-28
EP0817791A1 (en) 1998-01-14
JPH11503314A (ja) 1999-03-26
AU701345B2 (en) 1999-01-28
EP0817791A4 (en) 1998-07-15
MX9707549A (es) 1998-07-31
CN1190402A (zh) 1998-08-12
AU5531596A (en) 1996-10-16
CA2216878A1 (en) 1996-10-03
HUP9801767A3 (en) 1999-04-28
SK132797A3 (en) 1998-07-08
SI9620059A (sl) 1998-06-30
FR2732357B1 (fr) 1997-04-30
KR19980703454A (ko) 1998-11-05
WO1996030385A1 (en) 1996-10-03
OA10516A (en) 2002-04-22
US5851521A (en) 1998-12-22

Similar Documents

Publication Publication Date Title
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
BR9812134A (pt) Composição farmacêutica para tratamento de dismenorréia e parto prematuro
BR9909472A (pt) Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DK0701450T3 (da) Rekombinante viruser og deres anvendelse ved genterapi
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
DE69534165D1 (de) Adenovirus mit glutathion peroxydate gene
ATE285219T1 (de) Rekombinante haarbehandlungsmittel
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
BR9809951A (pt) Método para tratamento da obesidade
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
WO1999021574A3 (en) Enhancement of morphogen activity
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
HU9400290D0 (en) Pharmaceutical composition for preventing and treating retinal dieases
BR9611206A (pt) Utilização da proteína gax ou de uma variante da mesma e de pelo menos uma sequência nucleica que codifica completamente ou em parte a proteína gax ou de uma variante da mesma
BR9713514A (pt) Novo uso de creatina
IT1294967B1 (it) Composizione immunogenica da tlp
BR0013655A (pt) Uso de uma proteìna histacalina, e, método de tratamento ou de prevenção de rinite alérgica
NZ334762A (en) Human DNase I variants having binding affinity to actin

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]